Healthcare IT

Image

Asia-Pacific Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2030

  • Healthcare IT
  • Published Report
  • Mar 2023
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 249
  • No of Figures: 56

Asia-Pacific Gastric Cancer Diagnostics Market, By Product Type (Instruments, Reagents & Consumables, Services), Diagnostics Type (Confirmatory Test, Gastric Cancer Screening Tests/Physical Exam), Age Group (Adult, Pediatric, and Geriatrics), Disease Type (Intestinal Or Diffuse Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor (GIST), Gastric Lymphoma and Others), Stage (Stage 0, Stage I, Stage II, Stage III), Gender (Male and Female), Sample Type (Blood, Tissue, Urine, and Stool), End Users (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Distribution Channel (Direct Tenders and Retail Sales) - Industry Trends and Forecast to 2030.

Asia-Pacific Gastric Cancer Diagnostics Market

Asia-Pacific Gastric Cancer Diagnostics Market Analysis and Insights

The increase in the Asia-Pacific geriatric population is driving the growth of the gastric cancer diagnostics industry. The prevalence of gastrointestinal tumors and lymphomas has also fueled the demand for gastric cancer diagnostics. The key market constraint is the need to lower the high prices associated with cancer diagnostic testing so that even developing countries may benefit from it.

Asia-Pacific Gastric Cancer Diagnostics MarketAsia-Pacific Gastric Cancer Diagnostics Market

Large numbers of market players are offering gastric cancer diagnostics products with innovations that pave the way for the growth of the gastric cancer diagnostics market.

Data Bridge Market Research analyzes that the Asia-Pacific gastric cancer diagnostics market is expected to reach a value of USD 471.25 million by 2030, at a CAGR of 10.0% during the forecast period. Reagents and consumables account for the largest product type segment in the market due to rising demand for kits and reagents, and increasing health expenditures have accelerated the demand for smart medical devices.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customisable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Product Type (Instruments, Reagents & Consumables, Services), Diagnostics Type (Confirmatory Test, Gastric Cancer Screening Tests/Physical Exam), Age Group (Adult, Pediatric, and Geriatrics), Disease Type (Intestinal Or Diffuse Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor (GIST), Gastric Lymphoma and Others), Stage (Stage 0, Stage I, Stage II, Stage III), Gender (Male and Female), Sample Type (Blood, Tissue, Urine, and Stool), End Users (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Distribution Channel (Direct Tenders and Retail Sales)

Countries Covered

Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific

Market Players Covered

BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Vela Diagnostics, Abbott, AdvaCare Pharma, MiRXES, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, DiaSorin S.p.A, Paragon Genomics, Inc., and QIAGEN among others

Market Definition

Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below the ribs in the upper part of the abdomen. The stomach takes in and holds the food we eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for the diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scans, and ultrasound among others.

Cancer is caused by uncontrolled, abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer.

Asia-Pacific Gastric Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

 Drivers

  • Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma

According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.

It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.

Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the Asia-Pacific gastric cancer diagnostics market.

  • Rise in alcohol consumption and surge in smoking

Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone and so represents a severe public health issue that warrants further investigation.

A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.

Thus, the rise in alcohol consumption and surge in smoking is expected to drive the Asia-Pacific gastric cancer market growth.

Opportunity

  • Rise in adoption of automated systems

Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress.

Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for instance, is a new field focused on multidimensional data processing. It can also benefit from AI advancements.

Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.

Restraint/Challenge

  • Lack of sufficient financial support from health insurance policies

To achieve their objectives, health systems require financial resources. Human resources, hospital care, and medications are the most expensive aspects of most healthcare systems. In most tropical countries, health care is funded through a combination of government, private (mainly out-of-pocket) spending, and international help.

Healthcare finance remains a key concern for low- and lower-middle-income countries. Many upper-middle-income countries in Latin America, Africa, and Asia have been able to establish health finance arrangements that cover large segments of their populations. These measures enable access to health care while also protecting individuals from catastrophic debt incurred as a result of that access. Finance, on the other hand, is a major obstacle to health care delivery in low-income countries (the bulk of which are in Sub-Saharan Africa).

Thus, the lack of sufficient financial support from health insurance policies acts as a restraint to market's growth.

Recent Developments

  • In October 2022, General Electric Company collaborated with several research institutes such as the University of Cambridge Hospitals, Sophia Genetics, and earlier with Optellum to use imaging data in collaboration with Artificial intelligence. This will help to reduce the diagnosing time of several cancers and help to provide personalized care to patients. This has helped the company to widen its horizons in cancer diagnostics
  • In March 2020, Thermo Fisher Scientific Inc. announced that it would be acquiring QIAGEN, a Netherland-based molecular diagnostics and healthcare company. This acquisition by the company will increase its product portfolio in the market, leading to increased revenue in future

Asia-Pacific Gastric Cancer Diagnostics Market Scope

The Asia-Pacific gastric cancer diagnostics market is segmented into nine notable segments based on product type, diagnostic type, age group, disease type, stage, gender, sample, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

PRODUCT TYPE

  • Instruments
  • Reagents & Consumables
  • Services

On the basis of product type, the market is segmented into instruments, reagents & consumables, and services.

DIAGNOSTIC TYPE​​​​​​​

  • Confirmatory Test
  • Gastric Cancer Screening Tests/Physical Exam

On the basis of diagnostics type, the market is segmented into gastric cancer screening tests/physical exam and confirmatory tests.

AGE GROUP​​​​​​​

  • Adult
  • Pediatric
  • Geriatrics

On the basis of age group, the market is segmented into adult, pediatric, and geriatrics.

TYPE

  • Intestinal Or Diffuse Adenocarcinoma
  • Carcinoid Tumor
  • Gastrointestinal Stromal Tumor (GIST)
  • Gastric Lymphoma
  • Others

On the basis of type, the market is segmented into intestinal or diffuse adenocarcinoma, carcinoid tumor, gastrointestinal stromal tumor (GIST), gastric lymphoma, and others.

STAGE

  • Stage 0
  • Stage I
  • Stage II
  • Stage III

On the basis of stage, the market is segmented into stage 0, stage I, stage II, and stage III.

GENDER

  • Male
  • Female

On the basis of gender, the market is segmented into male and female.

SAMPLE TYPE​​​​​​​

  • Blood
  • Tissue
  • Urine
  • Stool

On the basis of sample type, the market is segmented into blood, tissue, urine, and stool.

END USER​​​​​​​

  • Diagnostic Laboratories
  • Hospitals
  • Cancer Research Institutes
  • Oncology Specialty Clinics
  • Others

On the basis of end users, the market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others.

DISTRIBUTION CHANNEL

  • Direct Tenders
  • Retail Sales

On the basis of distribution channel, the market is segmented into direct tender and retail sales.

Asia-Pacific Gastric Cancer Diagnostics Market Regional Analysis/Insights

The Asia-Pacific gastric cancer diagnostics market is segmented into nine notable segments based on product type, diagnostic type, age group, disease type, stage, gender, sample, end user, and distribution channel. 

The countries covered in this market report are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific.

South Korea is expected to dominate the Asia-Pacific gastric cancer diagnostics market due to increasing investments in medical device R&D and life sciences research.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Gastric Cancer Diagnostics Market Share Analysis

The Asia-Pacific gastric cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, product type lifeline curve. The above data points provided are only related to the company's focus on the Asia-Pacific gastric cancer diagnostics market.

Some of the major players operating in the market are BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Vela Diagnostics, Abbott, AdvaCare Pharma, MiRXES, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, DiaSorin S.p.A, Paragon Genomics, Inc., and QIAGEN among others.

 


SKU-

TABLE 1 APPROVED COMPANION DIAGNOSTIC DEVICE

TABLE 2 THE BELOW-MENTIONED LIST SHOWS THE COST OF PET SCAN FOR CANCER DIAGNOSIS IN DIFFERENT REGIONS ACROSS THE GLOBE-

TABLE 3 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 ASIA PACIFIC REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC REAGENT AND CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 ASIA PACIFIC KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 ASIA PACIFIC INSTRUMENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 ASIA PACIFIC SERVICES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 11 ASIA PACIFIC CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 ASIA PACIFIC CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 13 ASIA PACIFIC IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 14 ASIA PACIFIC BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 15 ASIA PACIFIC GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 17 ASIA PACIFIC GERIATRICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA PACIFIC ADULT IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 ASIA PACIFIC PEDIATRIC IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 21 ASIA PACIFIC INTESTINAL OR DIFFUSE ADENOCARCINOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA PACIFIC CARCINOID TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 ASIA PACIFIC GASTROINTESTINAL STROMAL TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 ASIA PACIFIC GASTRIC LYMPHOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 ASIA PACIFIC OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 27 ASIA PACIFIC STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 ASIA PACIFIC STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 29 ASIA PACIFIC STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA PACIFIC STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 31 ASIA PACIFIC STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA PACIFIC STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 33 ASIA PACIFIC STAGE 0 IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 35 ASIA PACIFIC MALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 ASIA PACIFIC FEMALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 38 ASIA PACIFIC STOOL IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 ASIA PACIFIC TISSUE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 ASIA PACIFIC BLOOD IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 ASIA PACIFIC URINE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 43 ASIA PACIFIC HOSPITALS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 ASIA PACIFIC DIAGNOSTIC LABORATORIES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 ASIA PACIFIC ONCOLOGY SPECIALTY CLINICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 ASIA PACIFIC OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 49 ASIA PACIFIC DIRECT TENDERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 ASIA PACIFIC RETAIL SALES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 ASIA-PACIFIC REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 56 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 57 ASIA-PACIFIC CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 58 ASIA-PACIFIC BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 59 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 60 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 61 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 62 ASIA-PACIFIC STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 63 ASIA-PACIFIC STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 64 ASIA-PACIFIC STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 65 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 66 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 67 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 68 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 69 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 70 SOUTH KOREA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 SOUTH KOREA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 72 SOUTH KOREA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 73 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 74 SOUTH KOREA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 75 SOUTH KOREA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 76 SOUTH KOREA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 77 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 78 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 79 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 80 SOUTH KOREA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 81 SOUTH KOREA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 82 SOUTH KOREA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 83 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 84 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 85 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 86 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 87 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 88 JAPAN REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 89 JAPAN KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 JAPAN REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 91 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 92 JAPAN CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 93 JAPAN IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 94 JAPAN BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 95 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 96 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 97 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 98 JAPAN STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 99 JAPAN STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 100 JAPAN STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 101 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 102 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 103 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 104 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 105 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 106 CHINA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 107 CHINA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 108 CHINA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 109 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 110 CHINA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 111 CHINA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 112 CHINA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 113 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 114 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 115 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 116 CHINA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 117 CHINA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 118 CHINA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 119 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 120 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 121 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 122 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 123 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 124 AUSTRALIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 125 AUSTRALIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 126 AUSTRALIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 127 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 128 AUSTRALIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 129 AUSTRALIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 130 AUSTRALIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 131 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 132 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 133 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 134 AUSTRALIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 135 AUSTRALIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 136 AUSTRALIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 137 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 138 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 139 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 140 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 141 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 142 SINGAPORE REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 143 SINGAPORE KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 144 SINGAPORE REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 145 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 146 SINGAPORE CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 147 SINGAPORE IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 148 SINGAPORE BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 149 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 150 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 151 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 152 SINGAPORE STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 153 SINGAPORE STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 154 SINGAPORE STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 155 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 156 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 157 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 158 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 159 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 160 INDIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 161 INDIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 162 INDIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 163 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 164 INDIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 165 INDIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 166 INDIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 167 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 168 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 169 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 170 INDIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 171 INDIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 172 INDIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 173 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 174 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 175 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 176 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 177 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 178 THAILAND REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 179 THAILAND KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 180 THAILAND REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 181 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 182 THAILAND CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 183 THAILAND IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 184 THAILAND BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 185 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 186 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 187 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 188 THAILAND STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 189 THAILAND STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 190 THAILAND STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 191 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 192 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 193 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 194 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 195 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 196 MALAYSIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 197 MALAYSIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 198 MALAYSIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 199 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 200 MALAYSIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 201 MALAYSIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 202 MALAYSIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 203 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 204 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 205 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 206 MALAYSIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 207 MALAYSIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 208 MALAYSIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 209 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 210 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 211 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 212 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 213 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 214 INDONESIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 215 INDONESIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 216 INDONESIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 217 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 218 INDONESIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 219 INDONESIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 220 INDONESIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 221 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 222 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 223 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 224 INDONESIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 225 INDONESIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 226 INDONESIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 227 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 228 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 229 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 230 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 231 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 232 PHILIPPINES REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 233 PHILIPPINES KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 234 PHILIPPINES REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 235 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 236 PHILIPPINES CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 237 PHILIPPINES IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 238 PHILIPPINES BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 239 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 240 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 241 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 242 PHILIPPINES STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 243 PHILIPPINES STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 244 PHILIPPINES STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 245 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 246 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 247 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 248 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 249 REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Asia-Pacific Gastric Cancer Diagnostics Market is projected to grow at a CAGR of 10.0% during the forecast period by 2030.
The future market value of the Asia-Pacific Gastric Cancer Diagnostics Market is expected to reach USD 471.25 million by 2030.
The major players in the Asia-Pacific Gastric Cancer Diagnostics Market are BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., etc.
The countries covered in the Asia-Pacific Gastric Cancer Diagnostics Market are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials